tirzepatide updates today 🚨 FDA Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like semaglutide and tirzepatide, signaling a major shift in how these Update from Big Easy on

Semaglutide: Semaglutide dominates the Liraglutide and Semaglutide Market Share with approximately 58.4% share in 2024, driven by superior clinical outcomes and broader application in both diabetes and obesity treatment

It also lowers the risk of major cardiovascular events such as stroke, heart attack, or death in adults with type 2 diabetes who also have heart disease, and lowers the risk of worsening kidney disease, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes who also have chronic kidney disease

But when you are staring at a growing welt on your stomach at 10 PM, mild is not the word that comes to mind

Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults

Experimental patches typically deliver 1030% of injected doses due to peptide size and skin absorption limits